<DOC>
	<DOCNO>NCT00207662</DOCNO>
	<brief_summary>This study infliximab ( Remicade ) subject Crohn 's disease</brief_summary>
	<brief_title>A Safety Efficacy Study Infliximab ( Remicade ) Patients With Moderate Severe Active Crohn 's Disease</brief_title>
	<detailed_description>Crohn 's disease disease characterize inflammation ( change happen tissue body injure ) ulceration ( formation pu ) bowel . The purpose study investigate safety therapeutic effect two different dos anti-TNFÎ± ( tumor necrosis factor ) antibody ( protein ) give multiple time compare single dose follow placebo ( inactive substance ) . The name antibody infliximab ( Remicade ) The goal study evaluate whether patient respond longer single dose infliximab repeat dos infliximab . Subjects receive infusion infliximab week 0 follow infusion infliximab placebo week 2 , 6 , 14 every 8 week week 54 . Patients lose response eligible additional infliximab treatment .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Men woman &gt; =18 year age Diagnosis Crohn 's Crohn 's disease least 3 month duration , colitis , ileitis , ileocolitis , confirm radiography endoscopy Local manifestation Crohn 's disease stricture , abscess , disease Surgery bowel diversion placement stoma within 3 month prior begin study Positive stool culture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>